Cost sharing for oral lenvatinib among commercially insured patients

CONCLUSIONS: In this cohort, insurance was liable for the majority of total lenvatinib drug costs, and 75% of patients paid $100 or less per month out of pocket. This information can be used by care teams to counsel insured patients. Health systems and drug manufacturers must identify patients with high out-of-pocket costs and provide convenient access to financial assistance programs so that patients are not forced to forgo the benefits of these drugs due to financial barriers. Value-based payment models and drug pricing reform are also needed to address underlying drivers of high drug costs.PMID:38457819 | DOI:10.37765/ajmc.2024.89512
Source: The American Journal of Managed Care - Category: Health Management Authors: Source Type: research